109 |
Update on the Endeavor I-V Trials: The Latest Results |
Ian T. Meredith |
Jul. 15. 05 |
108 |
Drug-Eluting Biodegradable Igaki-Tamai Stent |
|
Jul. 15. 05 |
107 |
ZoMaxx: Abbott's Drug Eluting Stent Program |
John Ormiston |
Jul. 15. 05 |
106 |
Everolimus Drug-Eluting Stents I: Review of Guidant FUTURE I and II, and Status Update of FUTURE III and IV |
Eberhard Grube |
Jul. 15. 05 |
105 |
DES for Complex Patients Subsets |
Alexandre Abizaid |
Jul. 15. 05 |
104 |
DES for Bifurcation Lesion |
Yean Teng Lim |
Jul. 15. 05 |
103 |
Coated vs Non-Coated Wires for CTO |
James R. Margolis |
Jul. 08. 05 |
102 |
Long Term Outcome of 1,000 CTO Cases |
Toshiya Muramatsu |
Jul. 08. 05 |
101 |
Zen Philosophy - The KEY to CTO Success |
Gregg W. Stone |
Jul. 08. 05 |
100 |
Lesson Learnt in the Complication Session at EuroPCR 2004 |
Eric Eeckhout |
Jul. 01. 05 |